English

    Overview

  • Dr. Tanmoy Kumar Mandal is a renowned medical oncologist practising at Manipal Hospitals, Dhakuria, Kolkata. He completed his MBBS from N.R.S Medical College, Kolkata, followed by an M.D. in General Medicine from Calcutta National Medical College, Kolkata. He further earned a specialisation by pursuing a D.M. in Medical Oncology from Tata Memorial Hospital, Mumbai. Additionally, he holds an MRCP in the field of Medical Oncology (Specialty Certificate Examination) and accomplished it in the year 2019, in the same year, he derived his ESMO certification, making him a certified practising consultant medical oncologist henceforth. He has also completed his Diploma in Tuberculosis and Chest Diseases (DTCD) and a DNB in Medical Oncology, further broadening his expertise in respiratory and oncological conditions.

  • Dr. Mandal specialises in the treatment of oncological and haematological disorders, managing solid tumours like gastrointestinal, genitourinary, lung, head and neck, gynaecological, breast cancers, and haematological malignancies like acute leukaemias, multiple myeloma, and lymphomas. His treatment modalities include Chemotherapy, Hormonal Therapy, Biological Therapy, or other targeted treatments. He has also been part of many clinical trials.

  • An incredibly dedicated professional, and titled to be the best medical oncologist in Kolkata, Dr. Mandal is widely known for his skills and commitment to the field of oncology. His dedication is reflected through several poster presentations and published papers, which have gained him praise from various national and international forums. Dr. Mandal is committed to helping cancer patients with accurate diagnoses and effective treatment plans to ensure swift recovery. His patients appreciate his compassion and dedication to providing quality treatment.

    • Field of Expertise

  • Specialises in diagnosing and treating various malignant disorders affecting the digestive system, including the oesophagus, stomach, intestines, and associated organs, enhancing patient outcomes.
  • Proficient in managing lung cancers using Immunotherapy and effectively handles the associated side effects, ensuring comprehensive care for his patients.
  • Expertise in treating blood cancers such as lymphoma and myeloma using Chemotherapy and Targeted Therapy, providing advanced and personalised treatment options for his patients.

    • Fellowship & Membership

  • European Society of Medical Oncologists (ESMO)
  • Indian Society of Medical and Paediatric Oncologists (ISMPO)
  • American Society of Clinical Oncologists (ASCO)
  • Immune-Oncological Society of India (IOSI)

    • Languages Spoken

  • Bengali
  • English
  • Hindi

    • Awards & Achievements

  • Real-world Eligibility for Treatment-Free Remission in Chronic Myeloid Leukaemia Patients-Report from a Tertiary Cancer Centre in India, presented at the International CML Conference-2017 (iCMLf)
  • Long-term and short-term outcomes in patients of chronic myeloid leukaemia treated with generic and innovator imatinib- a retrospective analysis, presented at the International CML Conference-2017 (iCMLf)
  • Outcomes of Chronic Myeloid Leukemia-Chronic Phase Patients Treated with Generic Imatinib- Report from Tata Memorial Hospital, oral presentation in Annual meeting of Mumbai Hematology Group, March 2018
  • Trastuzumab Emtansine in HER2 positive metastatic breast cancer: A real-world experience, E poster in ASCO- 2018, ASCO Abstract #226633
  • Chemotherapy-Induced Anemia / Zydus Cadila- Desidustat, Phase 1, Principal Investigator, 2021 - Clinical Trial
  • Non-small cell lung carcinoma / Pfizer- ICON PLC- Dacomitinib, Phase 4, Principal Investigator, 2021- Ongoing Clinical Trial
  • Breast / Ovarian / Prostate Cancer (NATCO Pharma / CBCC Global)- Olaparib, BA/BE, Principal Investigator, 2021 - Ongoing
  • Prostate Cancer/ Pfizer- ICON PLC- Talazoparib, Phase 3, Principal Investigator, 2021
  • Renal Cell Carcinoma/ Axis Clinicals- Sunitinib, BA/BE, Principal Investigator, 2021- Ongoing
  • Relapsed multiple myeloma- Carfilzomib- Amgen, Phase 4, Principal Investigator, 2021- Ongoing
  • SPEAR Registry- Novartis- PIK3CA testing observational, Principal Investigator, 2021- Ongoing

    • Talks & Publications

  • RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation, Oral Oncology, Volume 128,2022,105816, ISSN 1368-8375, https://doi.org/10.1016/j.oraloncology.2022.105816
  • Osteosarcoma journey over two decades in India: Small steps, big changes- Pediatric Blood Cancer. 2019;66:e27877. https://doi.org/10.1002/pbc.27877
  • Influence of hypothyroidism post chemoradiation on outcomes in head and neck cancer- DOI: 10.1200/JCO.2018.36.15_suppl.e18066 Journal of Clinical Oncology 36, no. 15_suppl. Published online June 01, 2018
  • Demography and pattern of care of patients with head-and-neck carcinoma: Experience from a tertiary care centre in North India- DOI: 10.4103/crst.crst_286_20
  • Outcomes of Patients with Splenic Marginal Zone Lymphoma Treated with Rituximab or Splenectomy: Report from Tertiary Cancer Center in India- DOI: https://doi.org/10.1016/j.clml.2018.07.216
  • Patil VM, Noronha V, Joshi A, Mandal TK, Bhattacharjee A, Goel A, et al. Hypothyroidism post-chemoradiation on outcomes in head-and-neck cancer. Cancer Res Stat Treat 2018; 1:84-91. https://www.crstonline.com/text.asp?2018/1/2/84/258535
  • Choudhary, A.K., Abraham, G., Patil, V.M. et al. Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors. Indian J Surg Oncol (2021). https://doi.org/10.1007/s13193-021-01445-y
  • Mandal TK, Roy S, Singh S, Lali BS, Chowdhury Z, Nayak L. Blastic plasmacytoid dendritic cell neoplasm of the thigh: A case report and narrative review of the literature. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Dec 8]; 3:630-4. Available from: https://www.crstonline.com/text.asp?2020/3/3/630/295540
  • Srinivas S, Roy S, Mandal TK, Das S. A Varanasi experience. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Dec 8];3:160-1. Available from: https://www.crstonline.com/text.asp?2020/3/1/160/279083
  • Kanteti, A.P.K., Abraham, G., Patil, V.M. et al. An Audit of Systemic Therapy in Medullary Carcinoma Thyroid. Indian J Surg Oncol (2021) https://doi.org/10.1007/s13193-021-01381-x
  • Roy S, Mandal TK, Nayak L, Gupta A, Shetty DL. Primary osseous burkitt lymphoma mimicking multiple myeloma – A case report and review of the literature. J Appl Hematol [serial online] 2021 [cited 2021 Dec 8];12:37-40. Available from: https://www.jahjournal.org/text.asp?2021/12/1/37/311324
  • Venetoclax – The Game-changer in Hematology- CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 555-558. DOI: 10.4103/ijmpo.ijmpo_260_20
  • Cutaneous Involvement of Systemic Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma- CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 239-240. DOI: 10.4103/ijmpo.ijmpo_72_20
  • Splenic marginal zone lymphoma relapsing as miliary lung mottling: an unusual presentation- DOI: https://doi.org/10.5045/br.2018.53.2.103
  • Subarachnoid haemorrhage caused by Moya Moya disease with no intracranial aneurysm-A rare case report. Indian Medical Journal, Volume-108, 15 December 2014 Annexure. pISSN No.-0091-5871
  • A case of Disseminated NCC infection as Immune Reconstitution Inflammatory Syndrome in an HIV patient"- Indian Medical Journal, Volume-108, 15 September 2014 Annexure. pISSN No.-0091-5871

    Fellowship & Membership

  • European Society of Medical Oncologists (ESMO)
  • Indian Society of Medical and Paediatric Oncologists (ISMPO)
  • American Society of Clinical Oncologists (ASCO)
  • Immune-Oncological Society of India (IOSI)

    • Overview

  • Dr. Tanmoy Kumar Mandal is a renowned medical oncologist practising at Manipal Hospitals, Dhakuria, Kolkata. He completed his MBBS from N.R.S Medical College, Kolkata, followed by an M.D. in General Medicine from Calcutta National Medical College, Kolkata. He further earned a specialisation by pursuing a D.M. in Medical Oncology from Tata Memorial Hospital, Mumbai. Additionally, he holds an MRCP in the field of Medical Oncology (Specialty Certificate Examination) and accomplished it in the year 2019, in the same year, he derived his ESMO certification, making him a certified practising consultant medical oncologist henceforth. He has also completed his Diploma in Tuberculosis and Chest Diseases (DTCD) and a DNB in Medical Oncology, further broadening his expertise in respiratory and oncological conditions.

  • Dr. Mandal specialises in the treatment of oncological and haematological disorders, managing solid tumours like gastrointestinal, genitourinary, lung, head and neck, gynaecological, breast cancers, and haematological malignancies like acute leukaemias, multiple myeloma, and lymphomas. His treatment modalities include Chemotherapy, Hormonal Therapy, Biological Therapy, or other targeted treatments. He has also been part of many clinical trials.

  • An incredibly dedicated professional, and titled to be the best medical oncologist in Kolkata, Dr. Mandal is widely known for his skills and commitment to the field of oncology. His dedication is reflected through several poster presentations and published papers, which have gained him praise from various national and international forums. Dr. Mandal is committed to helping cancer patients with accurate diagnoses and effective treatment plans to ensure swift recovery. His patients appreciate his compassion and dedication to providing quality treatment.

    • Field of Expertise

  • Specialises in diagnosing and treating various malignant disorders affecting the digestive system, including the oesophagus, stomach, intestines, and associated organs, enhancing patient outcomes.
  • Proficient in managing lung cancers using Immunotherapy and effectively handles the associated side effects, ensuring comprehensive care for his patients.
  • Expertise in treating blood cancers such as lymphoma and myeloma using Chemotherapy and Targeted Therapy, providing advanced and personalised treatment options for his patients.

    • Languages Spoken

  • Bengali
  • English
  • Hindi

    • Awards & Achievements

  • Real-world Eligibility for Treatment-Free Remission in Chronic Myeloid Leukaemia Patients-Report from a Tertiary Cancer Centre in India, presented at the International CML Conference-2017 (iCMLf)
  • Long-term and short-term outcomes in patients of chronic myeloid leukaemia treated with generic and innovator imatinib- a retrospective analysis, presented at the International CML Conference-2017 (iCMLf)
  • Outcomes of Chronic Myeloid Leukemia-Chronic Phase Patients Treated with Generic Imatinib- Report from Tata Memorial Hospital, oral presentation in Annual meeting of Mumbai Hematology Group, March 2018
  • Trastuzumab Emtansine in HER2 positive metastatic breast cancer: A real-world experience, E poster in ASCO- 2018, ASCO Abstract #226633
  • Chemotherapy-Induced Anemia / Zydus Cadila- Desidustat, Phase 1, Principal Investigator, 2021 - Clinical Trial
  • Non-small cell lung carcinoma / Pfizer- ICON PLC- Dacomitinib, Phase 4, Principal Investigator, 2021- Ongoing Clinical Trial
  • Breast / Ovarian / Prostate Cancer (NATCO Pharma / CBCC Global)- Olaparib, BA/BE, Principal Investigator, 2021 - Ongoing
  • Prostate Cancer/ Pfizer- ICON PLC- Talazoparib, Phase 3, Principal Investigator, 2021
  • Renal Cell Carcinoma/ Axis Clinicals- Sunitinib, BA/BE, Principal Investigator, 2021- Ongoing
  • Relapsed multiple myeloma- Carfilzomib- Amgen, Phase 4, Principal Investigator, 2021- Ongoing
  • SPEAR Registry- Novartis- PIK3CA testing observational, Principal Investigator, 2021- Ongoing

    • Talks & Publications

  • RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation, Oral Oncology, Volume 128,2022,105816, ISSN 1368-8375, https://doi.org/10.1016/j.oraloncology.2022.105816
  • Osteosarcoma journey over two decades in India: Small steps, big changes- Pediatric Blood Cancer. 2019;66:e27877. https://doi.org/10.1002/pbc.27877
  • Influence of hypothyroidism post chemoradiation on outcomes in head and neck cancer- DOI: 10.1200/JCO.2018.36.15_suppl.e18066 Journal of Clinical Oncology 36, no. 15_suppl. Published online June 01, 2018
  • Demography and pattern of care of patients with head-and-neck carcinoma: Experience from a tertiary care centre in North India- DOI: 10.4103/crst.crst_286_20
  • Outcomes of Patients with Splenic Marginal Zone Lymphoma Treated with Rituximab or Splenectomy: Report from Tertiary Cancer Center in India- DOI: https://doi.org/10.1016/j.clml.2018.07.216
  • Patil VM, Noronha V, Joshi A, Mandal TK, Bhattacharjee A, Goel A, et al. Hypothyroidism post-chemoradiation on outcomes in head-and-neck cancer. Cancer Res Stat Treat 2018; 1:84-91. https://www.crstonline.com/text.asp?2018/1/2/84/258535
  • Choudhary, A.K., Abraham, G., Patil, V.M. et al. Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors. Indian J Surg Oncol (2021). https://doi.org/10.1007/s13193-021-01445-y
  • Mandal TK, Roy S, Singh S, Lali BS, Chowdhury Z, Nayak L. Blastic plasmacytoid dendritic cell neoplasm of the thigh: A case report and narrative review of the literature. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Dec 8]; 3:630-4. Available from: https://www.crstonline.com/text.asp?2020/3/3/630/295540
  • Srinivas S, Roy S, Mandal TK, Das S. A Varanasi experience. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Dec 8];3:160-1. Available from: https://www.crstonline.com/text.asp?2020/3/1/160/279083
  • Kanteti, A.P.K., Abraham, G., Patil, V.M. et al. An Audit of Systemic Therapy in Medullary Carcinoma Thyroid. Indian J Surg Oncol (2021) https://doi.org/10.1007/s13193-021-01381-x
  • Roy S, Mandal TK, Nayak L, Gupta A, Shetty DL. Primary osseous burkitt lymphoma mimicking multiple myeloma – A case report and review of the literature. J Appl Hematol [serial online] 2021 [cited 2021 Dec 8];12:37-40. Available from: https://www.jahjournal.org/text.asp?2021/12/1/37/311324
  • Venetoclax – The Game-changer in Hematology- CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 555-558. DOI: 10.4103/ijmpo.ijmpo_260_20
  • Cutaneous Involvement of Systemic Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma- CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 239-240. DOI: 10.4103/ijmpo.ijmpo_72_20
  • Splenic marginal zone lymphoma relapsing as miliary lung mottling: an unusual presentation- DOI: https://doi.org/10.5045/br.2018.53.2.103
  • Subarachnoid haemorrhage caused by Moya Moya disease with no intracranial aneurysm-A rare case report. Indian Medical Journal, Volume-108, 15 December 2014 Annexure. pISSN No.-0091-5871
  • A case of Disseminated NCC infection as Immune Reconstitution Inflammatory Syndrome in an HIV patient"- Indian Medical Journal, Volume-108, 15 September 2014 Annexure. pISSN No.-0091-5871

    Languages Spoken

  • Bengali
  • English
  • Hindi

    • Overview

  • Dr. Tanmoy Kumar Mandal is a renowned medical oncologist practising at Manipal Hospitals, Dhakuria, Kolkata. He completed his MBBS from N.R.S Medical College, Kolkata, followed by an M.D. in General Medicine from Calcutta National Medical College, Kolkata. He further earned a specialisation by pursuing a D.M. in Medical Oncology from Tata Memorial Hospital, Mumbai. Additionally, he holds an MRCP in the field of Medical Oncology (Specialty Certificate Examination) and accomplished it in the year 2019, in the same year, he derived his ESMO certification, making him a certified practising consultant medical oncologist henceforth. He has also completed his Diploma in Tuberculosis and Chest Diseases (DTCD) and a DNB in Medical Oncology, further broadening his expertise in respiratory and oncological conditions.

  • Dr. Mandal specialises in the treatment of oncological and haematological disorders, managing solid tumours like gastrointestinal, genitourinary, lung, head and neck, gynaecological, breast cancers, and haematological malignancies like acute leukaemias, multiple myeloma, and lymphomas. His treatment modalities include Chemotherapy, Hormonal Therapy, Biological Therapy, or other targeted treatments. He has also been part of many clinical trials.

  • An incredibly dedicated professional, and titled to be the best medical oncologist in Kolkata, Dr. Mandal is widely known for his skills and commitment to the field of oncology. His dedication is reflected through several poster presentations and published papers, which have gained him praise from various national and international forums. Dr. Mandal is committed to helping cancer patients with accurate diagnoses and effective treatment plans to ensure swift recovery. His patients appreciate his compassion and dedication to providing quality treatment.

    • Fellowship & Membership

  • European Society of Medical Oncologists (ESMO)
  • Indian Society of Medical and Paediatric Oncologists (ISMPO)
  • American Society of Clinical Oncologists (ASCO)
  • Immune-Oncological Society of India (IOSI)

    • Field of Expertise

  • Specialises in diagnosing and treating various malignant disorders affecting the digestive system, including the oesophagus, stomach, intestines, and associated organs, enhancing patient outcomes.
  • Proficient in managing lung cancers using Immunotherapy and effectively handles the associated side effects, ensuring comprehensive care for his patients.
  • Expertise in treating blood cancers such as lymphoma and myeloma using Chemotherapy and Targeted Therapy, providing advanced and personalised treatment options for his patients.

    • Awards & Achievements

  • Real-world Eligibility for Treatment-Free Remission in Chronic Myeloid Leukaemia Patients-Report from a Tertiary Cancer Centre in India, presented at the International CML Conference-2017 (iCMLf)
  • Long-term and short-term outcomes in patients of chronic myeloid leukaemia treated with generic and innovator imatinib- a retrospective analysis, presented at the International CML Conference-2017 (iCMLf)
  • Outcomes of Chronic Myeloid Leukemia-Chronic Phase Patients Treated with Generic Imatinib- Report from Tata Memorial Hospital, oral presentation in Annual meeting of Mumbai Hematology Group, March 2018
  • Trastuzumab Emtansine in HER2 positive metastatic breast cancer: A real-world experience, E poster in ASCO- 2018, ASCO Abstract #226633
  • Chemotherapy-Induced Anemia / Zydus Cadila- Desidustat, Phase 1, Principal Investigator, 2021 - Clinical Trial
  • Non-small cell lung carcinoma / Pfizer- ICON PLC- Dacomitinib, Phase 4, Principal Investigator, 2021- Ongoing Clinical Trial
  • Breast / Ovarian / Prostate Cancer (NATCO Pharma / CBCC Global)- Olaparib, BA/BE, Principal Investigator, 2021 - Ongoing
  • Prostate Cancer/ Pfizer- ICON PLC- Talazoparib, Phase 3, Principal Investigator, 2021
  • Renal Cell Carcinoma/ Axis Clinicals- Sunitinib, BA/BE, Principal Investigator, 2021- Ongoing
  • Relapsed multiple myeloma- Carfilzomib- Amgen, Phase 4, Principal Investigator, 2021- Ongoing
  • SPEAR Registry- Novartis- PIK3CA testing observational, Principal Investigator, 2021- Ongoing

    • Talks & Publications

  • RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation, Oral Oncology, Volume 128,2022,105816, ISSN 1368-8375, https://doi.org/10.1016/j.oraloncology.2022.105816
  • Osteosarcoma journey over two decades in India: Small steps, big changes- Pediatric Blood Cancer. 2019;66:e27877. https://doi.org/10.1002/pbc.27877
  • Influence of hypothyroidism post chemoradiation on outcomes in head and neck cancer- DOI: 10.1200/JCO.2018.36.15_suppl.e18066 Journal of Clinical Oncology 36, no. 15_suppl. Published online June 01, 2018
  • Demography and pattern of care of patients with head-and-neck carcinoma: Experience from a tertiary care centre in North India- DOI: 10.4103/crst.crst_286_20
  • Outcomes of Patients with Splenic Marginal Zone Lymphoma Treated with Rituximab or Splenectomy: Report from Tertiary Cancer Center in India- DOI: https://doi.org/10.1016/j.clml.2018.07.216
  • Patil VM, Noronha V, Joshi A, Mandal TK, Bhattacharjee A, Goel A, et al. Hypothyroidism post-chemoradiation on outcomes in head-and-neck cancer. Cancer Res Stat Treat 2018; 1:84-91. https://www.crstonline.com/text.asp?2018/1/2/84/258535
  • Choudhary, A.K., Abraham, G., Patil, V.M. et al. Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors. Indian J Surg Oncol (2021). https://doi.org/10.1007/s13193-021-01445-y
  • Mandal TK, Roy S, Singh S, Lali BS, Chowdhury Z, Nayak L. Blastic plasmacytoid dendritic cell neoplasm of the thigh: A case report and narrative review of the literature. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Dec 8]; 3:630-4. Available from: https://www.crstonline.com/text.asp?2020/3/3/630/295540
  • Srinivas S, Roy S, Mandal TK, Das S. A Varanasi experience. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Dec 8];3:160-1. Available from: https://www.crstonline.com/text.asp?2020/3/1/160/279083
  • Kanteti, A.P.K., Abraham, G., Patil, V.M. et al. An Audit of Systemic Therapy in Medullary Carcinoma Thyroid. Indian J Surg Oncol (2021) https://doi.org/10.1007/s13193-021-01381-x
  • Roy S, Mandal TK, Nayak L, Gupta A, Shetty DL. Primary osseous burkitt lymphoma mimicking multiple myeloma – A case report and review of the literature. J Appl Hematol [serial online] 2021 [cited 2021 Dec 8];12:37-40. Available from: https://www.jahjournal.org/text.asp?2021/12/1/37/311324
  • Venetoclax – The Game-changer in Hematology- CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 555-558. DOI: 10.4103/ijmpo.ijmpo_260_20
  • Cutaneous Involvement of Systemic Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma- CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 239-240. DOI: 10.4103/ijmpo.ijmpo_72_20
  • Splenic marginal zone lymphoma relapsing as miliary lung mottling: an unusual presentation- DOI: https://doi.org/10.5045/br.2018.53.2.103
  • Subarachnoid haemorrhage caused by Moya Moya disease with no intracranial aneurysm-A rare case report. Indian Medical Journal, Volume-108, 15 December 2014 Annexure. pISSN No.-0091-5871
  • A case of Disseminated NCC infection as Immune Reconstitution Inflammatory Syndrome in an HIV patient"- Indian Medical Journal, Volume-108, 15 September 2014 Annexure. pISSN No.-0091-5871

    Field of Expertise

  • Specialises in diagnosing and treating various malignant disorders affecting the digestive system, including the oesophagus, stomach, intestines, and associated organs, enhancing patient outcomes.
  • Proficient in managing lung cancers using Immunotherapy and effectively handles the associated side effects, ensuring comprehensive care for his patients.
  • Expertise in treating blood cancers such as lymphoma and myeloma using Chemotherapy and Targeted Therapy, providing advanced and personalised treatment options for his patients.

    • Fellowship & Membership

  • European Society of Medical Oncologists (ESMO)
  • Indian Society of Medical and Paediatric Oncologists (ISMPO)
  • American Society of Clinical Oncologists (ASCO)
  • Immune-Oncological Society of India (IOSI)

    • Languages Spoken

  • Bengali
  • English
  • Hindi

    • Awards & Achievements

  • Real-world Eligibility for Treatment-Free Remission in Chronic Myeloid Leukaemia Patients-Report from a Tertiary Cancer Centre in India, presented at the International CML Conference-2017 (iCMLf)
  • Long-term and short-term outcomes in patients of chronic myeloid leukaemia treated with generic and innovator imatinib- a retrospective analysis, presented at the International CML Conference-2017 (iCMLf)
  • Outcomes of Chronic Myeloid Leukemia-Chronic Phase Patients Treated with Generic Imatinib- Report from Tata Memorial Hospital, oral presentation in Annual meeting of Mumbai Hematology Group, March 2018
  • Trastuzumab Emtansine in HER2 positive metastatic breast cancer: A real-world experience, E poster in ASCO- 2018, ASCO Abstract #226633
  • Chemotherapy-Induced Anemia / Zydus Cadila- Desidustat, Phase 1, Principal Investigator, 2021 - Clinical Trial
  • Non-small cell lung carcinoma / Pfizer- ICON PLC- Dacomitinib, Phase 4, Principal Investigator, 2021- Ongoing Clinical Trial
  • Breast / Ovarian / Prostate Cancer (NATCO Pharma / CBCC Global)- Olaparib, BA/BE, Principal Investigator, 2021 - Ongoing
  • Prostate Cancer/ Pfizer- ICON PLC- Talazoparib, Phase 3, Principal Investigator, 2021
  • Renal Cell Carcinoma/ Axis Clinicals- Sunitinib, BA/BE, Principal Investigator, 2021- Ongoing
  • Relapsed multiple myeloma- Carfilzomib- Amgen, Phase 4, Principal Investigator, 2021- Ongoing
  • SPEAR Registry- Novartis- PIK3CA testing observational, Principal Investigator, 2021- Ongoing

    • Talks & Publications

  • RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation, Oral Oncology, Volume 128,2022,105816, ISSN 1368-8375, https://doi.org/10.1016/j.oraloncology.2022.105816
  • Osteosarcoma journey over two decades in India: Small steps, big changes- Pediatric Blood Cancer. 2019;66:e27877. https://doi.org/10.1002/pbc.27877
  • Influence of hypothyroidism post chemoradiation on outcomes in head and neck cancer- DOI: 10.1200/JCO.2018.36.15_suppl.e18066 Journal of Clinical Oncology 36, no. 15_suppl. Published online June 01, 2018
  • Demography and pattern of care of patients with head-and-neck carcinoma: Experience from a tertiary care centre in North India- DOI: 10.4103/crst.crst_286_20
  • Outcomes of Patients with Splenic Marginal Zone Lymphoma Treated with Rituximab or Splenectomy: Report from Tertiary Cancer Center in India- DOI: https://doi.org/10.1016/j.clml.2018.07.216
  • Patil VM, Noronha V, Joshi A, Mandal TK, Bhattacharjee A, Goel A, et al. Hypothyroidism post-chemoradiation on outcomes in head-and-neck cancer. Cancer Res Stat Treat 2018; 1:84-91. https://www.crstonline.com/text.asp?2018/1/2/84/258535
  • Choudhary, A.K., Abraham, G., Patil, V.M. et al. Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors. Indian J Surg Oncol (2021). https://doi.org/10.1007/s13193-021-01445-y
  • Mandal TK, Roy S, Singh S, Lali BS, Chowdhury Z, Nayak L. Blastic plasmacytoid dendritic cell neoplasm of the thigh: A case report and narrative review of the literature. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Dec 8]; 3:630-4. Available from: https://www.crstonline.com/text.asp?2020/3/3/630/295540
  • Srinivas S, Roy S, Mandal TK, Das S. A Varanasi experience. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Dec 8];3:160-1. Available from: https://www.crstonline.com/text.asp?2020/3/1/160/279083
  • Kanteti, A.P.K., Abraham, G., Patil, V.M. et al. An Audit of Systemic Therapy in Medullary Carcinoma Thyroid. Indian J Surg Oncol (2021) https://doi.org/10.1007/s13193-021-01381-x
  • Roy S, Mandal TK, Nayak L, Gupta A, Shetty DL. Primary osseous burkitt lymphoma mimicking multiple myeloma – A case report and review of the literature. J Appl Hematol [serial online] 2021 [cited 2021 Dec 8];12:37-40. Available from: https://www.jahjournal.org/text.asp?2021/12/1/37/311324
  • Venetoclax – The Game-changer in Hematology- CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 555-558. DOI: 10.4103/ijmpo.ijmpo_260_20
  • Cutaneous Involvement of Systemic Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma- CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 239-240. DOI: 10.4103/ijmpo.ijmpo_72_20
  • Splenic marginal zone lymphoma relapsing as miliary lung mottling: an unusual presentation- DOI: https://doi.org/10.5045/br.2018.53.2.103
  • Subarachnoid haemorrhage caused by Moya Moya disease with no intracranial aneurysm-A rare case report. Indian Medical Journal, Volume-108, 15 December 2014 Annexure. pISSN No.-0091-5871
  • A case of Disseminated NCC infection as Immune Reconstitution Inflammatory Syndrome in an HIV patient"- Indian Medical Journal, Volume-108, 15 September 2014 Annexure. pISSN No.-0091-5871

    • Overview

  • Dr. Tanmoy Kumar Mandal is a renowned medical oncologist practising at Manipal Hospitals, Dhakuria, Kolkata. He completed his MBBS from N.R.S Medical College, Kolkata, followed by an M.D. in General Medicine from Calcutta National Medical College, Kolkata. He further earned a specialisation by pursuing a D.M. in Medical Oncology from Tata Memorial Hospital, Mumbai. Additionally, he holds an MRCP in the field of Medical Oncology (Specialty Certificate Examination) and accomplished it in the year 2019, in the same year, he derived his ESMO certification, making him a certified practising consultant medical oncologist henceforth. He has also completed his Diploma in Tuberculosis and Chest Diseases (DTCD) and a DNB in Medical Oncology, further broadening his expertise in respiratory and oncological conditions.

  • Dr. Mandal specialises in the treatment of oncological and haematological disorders, managing solid tumours like gastrointestinal, genitourinary, lung, head and neck, gynaecological, breast cancers, and haematological malignancies like acute leukaemias, multiple myeloma, and lymphomas. His treatment modalities include Chemotherapy, Hormonal Therapy, Biological Therapy, or other targeted treatments. He has also been part of many clinical trials.

  • An incredibly dedicated professional, and titled to be the best medical oncologist in Kolkata, Dr. Mandal is widely known for his skills and commitment to the field of oncology. His dedication is reflected through several poster presentations and published papers, which have gained him praise from various national and international forums. Dr. Mandal is committed to helping cancer patients with accurate diagnoses and effective treatment plans to ensure swift recovery. His patients appreciate his compassion and dedication to providing quality treatment.

    Awards & Achievements

  • Real-world Eligibility for Treatment-Free Remission in Chronic Myeloid Leukaemia Patients-Report from a Tertiary Cancer Centre in India, presented at the International CML Conference-2017 (iCMLf)
  • Long-term and short-term outcomes in patients of chronic myeloid leukaemia treated with generic and innovator imatinib- a retrospective analysis, presented at the International CML Conference-2017 (iCMLf)
  • Outcomes of Chronic Myeloid Leukemia-Chronic Phase Patients Treated with Generic Imatinib- Report from Tata Memorial Hospital, oral presentation in Annual meeting of Mumbai Hematology Group, March 2018
  • Trastuzumab Emtansine in HER2 positive metastatic breast cancer: A real-world experience, E poster in ASCO- 2018, ASCO Abstract #226633
  • Chemotherapy-Induced Anemia / Zydus Cadila- Desidustat, Phase 1, Principal Investigator, 2021 - Clinical Trial
  • Non-small cell lung carcinoma / Pfizer- ICON PLC- Dacomitinib, Phase 4, Principal Investigator, 2021- Ongoing Clinical Trial
  • Breast / Ovarian / Prostate Cancer (NATCO Pharma / CBCC Global)- Olaparib, BA/BE, Principal Investigator, 2021 - Ongoing
  • Prostate Cancer/ Pfizer- ICON PLC- Talazoparib, Phase 3, Principal Investigator, 2021
  • Renal Cell Carcinoma/ Axis Clinicals- Sunitinib, BA/BE, Principal Investigator, 2021- Ongoing
  • Relapsed multiple myeloma- Carfilzomib- Amgen, Phase 4, Principal Investigator, 2021- Ongoing
  • SPEAR Registry- Novartis- PIK3CA testing observational, Principal Investigator, 2021- Ongoing

    • Fellowship & Membership

  • European Society of Medical Oncologists (ESMO)
  • Indian Society of Medical and Paediatric Oncologists (ISMPO)
  • American Society of Clinical Oncologists (ASCO)
  • Immune-Oncological Society of India (IOSI)

    • Field of Expertise

  • Specialises in diagnosing and treating various malignant disorders affecting the digestive system, including the oesophagus, stomach, intestines, and associated organs, enhancing patient outcomes.
  • Proficient in managing lung cancers using Immunotherapy and effectively handles the associated side effects, ensuring comprehensive care for his patients.
  • Expertise in treating blood cancers such as lymphoma and myeloma using Chemotherapy and Targeted Therapy, providing advanced and personalised treatment options for his patients.

    • Languages Spoken

  • Bengali
  • English
  • Hindi

    • Talks & Publications

  • RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation, Oral Oncology, Volume 128,2022,105816, ISSN 1368-8375, https://doi.org/10.1016/j.oraloncology.2022.105816
  • Osteosarcoma journey over two decades in India: Small steps, big changes- Pediatric Blood Cancer. 2019;66:e27877. https://doi.org/10.1002/pbc.27877
  • Influence of hypothyroidism post chemoradiation on outcomes in head and neck cancer- DOI: 10.1200/JCO.2018.36.15_suppl.e18066 Journal of Clinical Oncology 36, no. 15_suppl. Published online June 01, 2018
  • Demography and pattern of care of patients with head-and-neck carcinoma: Experience from a tertiary care centre in North India- DOI: 10.4103/crst.crst_286_20
  • Outcomes of Patients with Splenic Marginal Zone Lymphoma Treated with Rituximab or Splenectomy: Report from Tertiary Cancer Center in India- DOI: https://doi.org/10.1016/j.clml.2018.07.216
  • Patil VM, Noronha V, Joshi A, Mandal TK, Bhattacharjee A, Goel A, et al. Hypothyroidism post-chemoradiation on outcomes in head-and-neck cancer. Cancer Res Stat Treat 2018; 1:84-91. https://www.crstonline.com/text.asp?2018/1/2/84/258535
  • Choudhary, A.K., Abraham, G., Patil, V.M. et al. Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors. Indian J Surg Oncol (2021). https://doi.org/10.1007/s13193-021-01445-y
  • Mandal TK, Roy S, Singh S, Lali BS, Chowdhury Z, Nayak L. Blastic plasmacytoid dendritic cell neoplasm of the thigh: A case report and narrative review of the literature. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Dec 8]; 3:630-4. Available from: https://www.crstonline.com/text.asp?2020/3/3/630/295540
  • Srinivas S, Roy S, Mandal TK, Das S. A Varanasi experience. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Dec 8];3:160-1. Available from: https://www.crstonline.com/text.asp?2020/3/1/160/279083
  • Kanteti, A.P.K., Abraham, G., Patil, V.M. et al. An Audit of Systemic Therapy in Medullary Carcinoma Thyroid. Indian J Surg Oncol (2021) https://doi.org/10.1007/s13193-021-01381-x
  • Roy S, Mandal TK, Nayak L, Gupta A, Shetty DL. Primary osseous burkitt lymphoma mimicking multiple myeloma – A case report and review of the literature. J Appl Hematol [serial online] 2021 [cited 2021 Dec 8];12:37-40. Available from: https://www.jahjournal.org/text.asp?2021/12/1/37/311324
  • Venetoclax – The Game-changer in Hematology- CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 555-558. DOI: 10.4103/ijmpo.ijmpo_260_20
  • Cutaneous Involvement of Systemic Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma- CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 239-240. DOI: 10.4103/ijmpo.ijmpo_72_20
  • Splenic marginal zone lymphoma relapsing as miliary lung mottling: an unusual presentation- DOI: https://doi.org/10.5045/br.2018.53.2.103
  • Subarachnoid haemorrhage caused by Moya Moya disease with no intracranial aneurysm-A rare case report. Indian Medical Journal, Volume-108, 15 December 2014 Annexure. pISSN No.-0091-5871
  • A case of Disseminated NCC infection as Immune Reconstitution Inflammatory Syndrome in an HIV patient"- Indian Medical Journal, Volume-108, 15 September 2014 Annexure. pISSN No.-0091-5871

    • Overview

  • Dr. Tanmoy Kumar Mandal is a renowned medical oncologist practising at Manipal Hospitals, Dhakuria, Kolkata. He completed his MBBS from N.R.S Medical College, Kolkata, followed by an M.D. in General Medicine from Calcutta National Medical College, Kolkata. He further earned a specialisation by pursuing a D.M. in Medical Oncology from Tata Memorial Hospital, Mumbai. Additionally, he holds an MRCP in the field of Medical Oncology (Specialty Certificate Examination) and accomplished it in the year 2019, in the same year, he derived his ESMO certification, making him a certified practising consultant medical oncologist henceforth. He has also completed his Diploma in Tuberculosis and Chest Diseases (DTCD) and a DNB in Medical Oncology, further broadening his expertise in respiratory and oncological conditions.

  • Dr. Mandal specialises in the treatment of oncological and haematological disorders, managing solid tumours like gastrointestinal, genitourinary, lung, head and neck, gynaecological, breast cancers, and haematological malignancies like acute leukaemias, multiple myeloma, and lymphomas. His treatment modalities include Chemotherapy, Hormonal Therapy, Biological Therapy, or other targeted treatments. He has also been part of many clinical trials.

  • An incredibly dedicated professional, and titled to be the best medical oncologist in Kolkata, Dr. Mandal is widely known for his skills and commitment to the field of oncology. His dedication is reflected through several poster presentations and published papers, which have gained him praise from various national and international forums. Dr. Mandal is committed to helping cancer patients with accurate diagnoses and effective treatment plans to ensure swift recovery. His patients appreciate his compassion and dedication to providing quality treatment.

    Talks & Publications

  • RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation, Oral Oncology, Volume 128,2022,105816, ISSN 1368-8375, https://doi.org/10.1016/j.oraloncology.2022.105816
  • Osteosarcoma journey over two decades in India: Small steps, big changes- Pediatric Blood Cancer. 2019;66:e27877. https://doi.org/10.1002/pbc.27877
  • Influence of hypothyroidism post chemoradiation on outcomes in head and neck cancer- DOI: 10.1200/JCO.2018.36.15_suppl.e18066 Journal of Clinical Oncology 36, no. 15_suppl. Published online June 01, 2018
  • Demography and pattern of care of patients with head-and-neck carcinoma: Experience from a tertiary care centre in North India- DOI: 10.4103/crst.crst_286_20
  • Outcomes of Patients with Splenic Marginal Zone Lymphoma Treated with Rituximab or Splenectomy: Report from Tertiary Cancer Center in India- DOI: https://doi.org/10.1016/j.clml.2018.07.216
  • Patil VM, Noronha V, Joshi A, Mandal TK, Bhattacharjee A, Goel A, et al. Hypothyroidism post-chemoradiation on outcomes in head-and-neck cancer. Cancer Res Stat Treat 2018; 1:84-91. https://www.crstonline.com/text.asp?2018/1/2/84/258535
  • Choudhary, A.K., Abraham, G., Patil, V.M. et al. Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors. Indian J Surg Oncol (2021). https://doi.org/10.1007/s13193-021-01445-y
  • Mandal TK, Roy S, Singh S, Lali BS, Chowdhury Z, Nayak L. Blastic plasmacytoid dendritic cell neoplasm of the thigh: A case report and narrative review of the literature. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Dec 8]; 3:630-4. Available from: https://www.crstonline.com/text.asp?2020/3/3/630/295540
  • Srinivas S, Roy S, Mandal TK, Das S. A Varanasi experience. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Dec 8];3:160-1. Available from: https://www.crstonline.com/text.asp?2020/3/1/160/279083
  • Kanteti, A.P.K., Abraham, G., Patil, V.M. et al. An Audit of Systemic Therapy in Medullary Carcinoma Thyroid. Indian J Surg Oncol (2021) https://doi.org/10.1007/s13193-021-01381-x
  • Roy S, Mandal TK, Nayak L, Gupta A, Shetty DL. Primary osseous burkitt lymphoma mimicking multiple myeloma – A case report and review of the literature. J Appl Hematol [serial online] 2021 [cited 2021 Dec 8];12:37-40. Available from: https://www.jahjournal.org/text.asp?2021/12/1/37/311324
  • Venetoclax – The Game-changer in Hematology- CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 555-558. DOI: 10.4103/ijmpo.ijmpo_260_20
  • Cutaneous Involvement of Systemic Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma- CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 239-240. DOI: 10.4103/ijmpo.ijmpo_72_20
  • Splenic marginal zone lymphoma relapsing as miliary lung mottling: an unusual presentation- DOI: https://doi.org/10.5045/br.2018.53.2.103
  • Subarachnoid haemorrhage caused by Moya Moya disease with no intracranial aneurysm-A rare case report. Indian Medical Journal, Volume-108, 15 December 2014 Annexure. pISSN No.-0091-5871
  • A case of Disseminated NCC infection as Immune Reconstitution Inflammatory Syndrome in an HIV patient"- Indian Medical Journal, Volume-108, 15 September 2014 Annexure. pISSN No.-0091-5871

    • Overview

  • Dr. Tanmoy Kumar Mandal is a renowned medical oncologist practising at Manipal Hospitals, Dhakuria, Kolkata. He completed his MBBS from N.R.S Medical College, Kolkata, followed by an M.D. in General Medicine from Calcutta National Medical College, Kolkata. He further earned a specialisation by pursuing a D.M. in Medical Oncology from Tata Memorial Hospital, Mumbai. Additionally, he holds an MRCP in the field of Medical Oncology (Specialty Certificate Examination) and accomplished it in the year 2019, in the same year, he derived his ESMO certification, making him a certified practising consultant medical oncologist henceforth. He has also completed his Diploma in Tuberculosis and Chest Diseases (DTCD) and a DNB in Medical Oncology, further broadening his expertise in respiratory and oncological conditions.

  • Dr. Mandal specialises in the treatment of oncological and haematological disorders, managing solid tumours like gastrointestinal, genitourinary, lung, head and neck, gynaecological, breast cancers, and haematological malignancies like acute leukaemias, multiple myeloma, and lymphomas. His treatment modalities include Chemotherapy, Hormonal Therapy, Biological Therapy, or other targeted treatments. He has also been part of many clinical trials.

  • An incredibly dedicated professional, and titled to be the best medical oncologist in Kolkata, Dr. Mandal is widely known for his skills and commitment to the field of oncology. His dedication is reflected through several poster presentations and published papers, which have gained him praise from various national and international forums. Dr. Mandal is committed to helping cancer patients with accurate diagnoses and effective treatment plans to ensure swift recovery. His patients appreciate his compassion and dedication to providing quality treatment.

    • Fellowship & Membership

  • European Society of Medical Oncologists (ESMO)
  • Indian Society of Medical and Paediatric Oncologists (ISMPO)
  • American Society of Clinical Oncologists (ASCO)
  • Immune-Oncological Society of India (IOSI)

    • Field of Expertise

  • Specialises in diagnosing and treating various malignant disorders affecting the digestive system, including the oesophagus, stomach, intestines, and associated organs, enhancing patient outcomes.
  • Proficient in managing lung cancers using Immunotherapy and effectively handles the associated side effects, ensuring comprehensive care for his patients.
  • Expertise in treating blood cancers such as lymphoma and myeloma using Chemotherapy and Targeted Therapy, providing advanced and personalised treatment options for his patients.

    • Languages Spoken

  • Bengali
  • English
  • Hindi

    • Awards & Achievements

  • Real-world Eligibility for Treatment-Free Remission in Chronic Myeloid Leukaemia Patients-Report from a Tertiary Cancer Centre in India, presented at the International CML Conference-2017 (iCMLf)
  • Long-term and short-term outcomes in patients of chronic myeloid leukaemia treated with generic and innovator imatinib- a retrospective analysis, presented at the International CML Conference-2017 (iCMLf)
  • Outcomes of Chronic Myeloid Leukemia-Chronic Phase Patients Treated with Generic Imatinib- Report from Tata Memorial Hospital, oral presentation in Annual meeting of Mumbai Hematology Group, March 2018
  • Trastuzumab Emtansine in HER2 positive metastatic breast cancer: A real-world experience, E poster in ASCO- 2018, ASCO Abstract #226633
  • Chemotherapy-Induced Anemia / Zydus Cadila- Desidustat, Phase 1, Principal Investigator, 2021 - Clinical Trial
  • Non-small cell lung carcinoma / Pfizer- ICON PLC- Dacomitinib, Phase 4, Principal Investigator, 2021- Ongoing Clinical Trial
  • Breast / Ovarian / Prostate Cancer (NATCO Pharma / CBCC Global)- Olaparib, BA/BE, Principal Investigator, 2021 - Ongoing
  • Prostate Cancer/ Pfizer- ICON PLC- Talazoparib, Phase 3, Principal Investigator, 2021
  • Renal Cell Carcinoma/ Axis Clinicals- Sunitinib, BA/BE, Principal Investigator, 2021- Ongoing
  • Relapsed multiple myeloma- Carfilzomib- Amgen, Phase 4, Principal Investigator, 2021- Ongoing
  • SPEAR Registry- Novartis- PIK3CA testing observational, Principal Investigator, 2021- Ongoing

FAQ's

Patients often seek Dr. Tanmoy Kumar Mandal’s expertise as the Consultant - Medical Oncology at Manipal Hospitals Dhakuria. Consult with the best Medical Oncologist in Kolkata. Dr Tanmoy Kumar Mandal specialises in the treatment of oncological and haematological disorders.

Home Dhakuria Doctors Dr-tanmoy-kumar-mandal-medical-oncologist

Appointment
Health Check
Contact Us
review icon
Review Us
Call Us